GlassScriptPhysician profile
Sarah Nobles
NPI 1093584054
$3,780.02
in general payments reported to CMS, 2019-2025
22 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,120 · 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.29 |
| Education | $350.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $587.97 | 2024-2025 | |
| Abbvie INC. | $516.11 | 2024-2025 | |
| Leo Pharma INC. | $469.22 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Biotech, INC. | $337.74 | 2024-2025 | Tremfya |
| Ucb, INC. | $267.56 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $251.83 | 2024-2025 | |
| Hill Dermaceuticals, INC. | $195.91 | 2025 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $194.02 | 2025 | Sotyktu |
| Galderma Laboratories, L.P. | $170.58 | 2024-2025 | Nemluvio, Dysport |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.81 | 2024-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Lilly USA, LLC | $87.49 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $79.91 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $79.61 | 2025 | |
| Organon LLC | $71.45 | 2025 | Nexplanon |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.30 | 2025 | Dupixent |
| Biofrontera INC. | $58.38 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $39.21 | 2025 | Opzelura |
| Genentech USA, INC. | $31.95 | 2024 | Erivedge |
| Novartis Pharmaceuticals Corporation | $27.43 | 2024 | |
| Almirall LLC | $21.42 | 2024 | Klisyri |
| Botanix Sb INC | $16.13 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Nobles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.